SOHO state of the art updates and next questions: Will CAR-T replace ASCT in NDMM Review


Authors: Jurgens, E.; Usmani, S. Z.
Review Title: SOHO state of the art updates and next questions: Will CAR-T replace ASCT in NDMM
Abstract: The treatment landscape for multiple myeloma (MM) has rapidly evolved over the last 2 decades. The development of triplet and quadruplet regimens including proteasome inhibitors (PI), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies has dramatically extended overall survival. In addition to effective multidrug regimens, autologous stem cell transplant (ASCT) is a cornerstone of management in newly diagnosed multiple myeloma (NDMM). However, despite these combined treatment modalities, curative therapy for MM remains elusive. Recent, novel immunotherapies including chimeric antigen T-cell (CAR-T) therapy have demonstrated deep and durable responses in relapsed and refractory multiple myeloma (RRMM). Currently 2 CAR-T products, ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), are approved by the FDA for the treatment of RRMM. The success of CAR-T therapy revolutionized the management of RRMM prompting clinical trials studying CAR-T therapy in the first line setting. The ongoing KarMMa-4, CARTITUDE-5, and CARTITUDE-6 clinical trials may establish CAR-T therapy as a first line option potentially supplanting ASCT in the initial treatment of NDMM. In this review, we discuss the current standard of care management of NDMM, trace the evolution of CAR-T clinical trials in RRMM, and survey ongoing clinical trials studying CAR-T therapy in NDMM. © 2024 Elsevier Inc.
Keywords: multiple myeloma; minimal residual disease; relapsed; chimeric antigen receptors; newly diagnosed
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 24
Issue: 5
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2024-05-01
Start Page: 277
End Page: 284
Language: English
DOI: 10.1016/j.clml.2024.01.001
PUBMED: 38331676
PROVIDER: scopus
DOI/URL:
Notes: Review -- MSK corresponding author is Saad Usmani -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Saad Zafar Usmani
    297 Usmani
  2. Eric Jurgens
    14 Jurgens